Gut Microbiota conversion of dietary ellagic acid into bioactive phytoceutical urolithin a inhibits heme peroxidases

Article abstract of DOI:10.1371/journal.pone.0156811

Numerous studies signify that diets rich in phytochemicals offer many beneficial functions specifically during pathologic conditions, yet their effects are often not uniform due to interindividual variation. The host indigenous gut microbiota and their modifications of dietary phytochemicals have emerged as factors that greatly influence the efficacy of phytoceutical- based intervention. Here, we investigated the biological activities of one such active microbial metabolite, Urolithin A (UA or 3,8-dihydroxybenzo[c]chromen-6-one), which is derived from the ellagic acid (EA). Our study demonstrates that UA potently inhibits heme peroxidases i.e. myeloperoxidase (MPO) and lactoperoxidase (LPO) when compared to the parent compound EA. In addition, chrome azurol S (CAS) assay suggests that EA, but not UA, is capable of binding to Fe³⁺, due to its catechol-like structure, although its modest heme peroxidase inhibitory activity is abrogated upon Fe³⁺-binding. Interestingly, UA-mediated MPO and LPO inhibition can be prevented by innate immune protein human NGAL or its murine ortholog lipocalin 2 (Lcn2), implying the complex nature of host innate immunitymicrobiota interactions. Spectral analysis indicates that UA inhibits heme peroxidase-catalyzed reaction by reverting the peroxidase back to its inactive native state. In support of these in vitro results, UA significantly reduced phorbol myristate acetate (PMA)-induced superoxide generation in neutrophils, however, EA failed to block the superoxide generation. Treatment with UA significantly reduced PMA-induced mouse ear edema and MPO activity compared to EA treated mice. Collectively, our results demonstrate that microbiotamediated conversion of EA to UA is advantageous to both host and microbiota i.e. UA-mediated inhibition of pro-oxidant enzymes reduce tissue inflammation, mitigate non-specific killing of gut bacteria, and abrogate iron-binding property of EA, thus providing a competitive edge to the microbiota in acquiring limiting nutrient iron and thrive in the gut.

Full text of DOI:10.1371/journal.pone.0156811

RESEARCH ARTICLE
Gut Microbiota Conversion of Dietary Ellagic
Acid into Bioactive Phytoceutical Urolithin A
Inhibits Heme Peroxidases
1
1
3
4
Piu Saha , Beng San Yeoh , Rajbir Singh , Bhargavi Chandrasekar , Praveen
4
,5
3
1,2‡
Kumar Vemula , Bodduluri Haribabu , Matam Vijay-Kumar *, Venkatakrishna
R. Jala *
3
‡
1
Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania,
United States of America, 2 Department of Medicine, The Pennsylvania State University Medical Center,
Hershey, Pennsylvania, United States of America, 3 Department of Microbiology and Immunology, James
Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, United States of America,
4
Institute for Stem Cell Biology and Regenerative Medicine (inStem), UAS-GKVK Campus, Bellary Road,
Bangalore, Karnataka, India, 5 Ramalingaswami ReEntry Fellow, Dept. of Biotechnology, Govt. of India
‡
MVK and VRJ are joint senior authors on this work.
mvk13@psu.edu (MVK); jvrao001@louisville.edu (VRJ)
a11111
*
Abstract
Numerous studies signify that diets rich in phytochemicals offer many beneficial functions
specifically during pathologic conditions, yet their effects are often not uniform due to inter-
individual variation. The host indigenous gut microbiota and their modifications of dietary
phytochemicals have emerged as factors that greatly influence the efficacy of phytoceuti-
cal-based intervention. Here, we investigated the biological activities of one such active
microbial metabolite, Urolithin A (UA or 3,8-dihydroxybenzo[c]chromen-6-one), which is
derived from the ellagic acid (EA). Our study demonstrates that UA potently inhibits heme
peroxidases i.e. myeloperoxidase (MPO) and lactoperoxidase (LPO) when compared to the
parent compound EA. In addition, chrome azurol S (CAS) assay suggests that EA, but not
OPEN ACCESS
Citation: Saha P, Yeoh BS, Singh R, Chandrasekar
B, Vemula PK, Haribabu B, et al. (2016) Gut
Microbiota Conversion of Dietary Ellagic Acid into
Bioactive Phytoceutical Urolithin A Inhibits Heme
Peroxidases. PLoS ONE 11(6): e0156811.
doi:10.1371/journal.pone.0156811
Editor: Luca Vanella, University of Catania, ITALY
Received: April 26, 2016
3+
UA, is capable of binding to Fe , due to its catechol-like structure, although its modest
3
+
Accepted: May 19, 2016
heme peroxidase inhibitory activity is abrogated upon Fe -binding. Interestingly, UA-medi-
ated MPO and LPO inhibition can be prevented by innate immune protein human NGAL or
its murine ortholog lipocalin 2 (Lcn2), implying the complex nature of host innate immunity-
microbiota interactions. Spectral analysis indicates that UA inhibits heme peroxidase-cata-
Published: June 2, 2016
Copyright: © 2016 Saha et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits lyzed reaction by reverting the peroxidase back to its inactive native state. In support of
unrestricted use, distribution, and reproduction in any
these in vitro results, UA significantly reduced phorbol myristate acetate (PMA)-induced
medium, provided the original author and source are
superoxide generation in neutrophils, however, EA failed to block the superoxide genera-
credited.
tion. Treatment with UA significantly reduced PMA-induced mouse ear edema and MPO
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
activity compared to EA treated mice. Collectively, our results demonstrate that microbiota-
mediated conversion of EA to UA is advantageous to both host and microbiota i.e. UA-medi-
Funding: The studies were supported by a pilot grant
to VRJ from Dept. Microbiology and Immunology and
ated inhibition of pro-oxidant enzymes reduce tissue inflammation, mitigate non-specific kill-
ing of gut bacteria, and abrogate iron-binding property of EA, thus providing a competitive
edge to the microbiota in acquiring limiting nutrient iron and thrive in the gut.
JGBCC, University of Louisville, Louisville, KY.
Competing Interests: The authors have declared
that no competing interests exist.
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
1 / 21

Urolithin A Controls Neutrophilic Inflammation
Introduction
Gut microbiota is considered as hidden metabolic ‘organ within an organ’ because of its
immense effect on health by influencing the host nutrient acquisition, metabolism, physiology,
and immune functions [1–4]. The human gastrointestinal tract (GIT) harbours complex
14
microbial community as high as up to ~10 microorganisms. One of the major functions of
gut microbiota is to metabolize dietary components to a spectrum of metabolites. Several of
these microbial-derived metabolites aid in developing and controlling immune system not only
in the gut but also distant organs. The balance between microbial controlled pro and anti-
inflammatory activities is critical to maintain gut homeostasis and regulate gut inflammation
and colon carcinogenesis [5–10]. Several external factors such as infection, diet and usage of
antibiotics are known to disrupt the dynamics of microbial communities in the intestine and
the host immune system [8, 11–17]. Efforts are currently underway to define complex micro-
biota-host interactions (good vs bad; cause vs consequence) using animal models in germ-free
conditions and antibiotic-mediated microbiota ablation [15, 18–21]. However, given the com-
plexity of gut microbiota and their metabolites, it is difficult to predict which specific bacterial
pool is responsible for beneficial or opportunistic/pathogenic effects solely based on micro-
biota/metagenomics analysis. Further, the influence of microbial metabolites in immune-mod-
ulatory function adds another layer of complexity.
The health benefits rendered by consumption of several natural plant products (e.g., pome-
granates, walnuts and berries) have been associated with their high levels of health promoting
polyphenolic compounds, specifically ellagitannins and EA [22–24]. These compounds display
protective effects against chronic metabolic disorders both in preclinical and clinical studies
[24–30]. The beneficial effects of EA are associated with multi-target action that involve anti-
inflammatory, anti-oxidant and anti-carcinogenic effects [24, 31]. However, the intestinal
absorption (bioavailability) of ellagitannins and EA is limited [32–34]. Recently, Gonzalez-Sar-
rias et al demonstrated the limits for EA bioavailability in healthy volunteers after consumption
of pomegranate extracts [35]. These studies reported that EA bioavailability is not as low as
previously described. However, pharmacokinetics suggested that there is high inter-individual
variation of EA bioavailability Cmax ranging from 12 to 360 nm [35]. It has been suggested
that potential health benefits rendered by these compounds in vivo are due to gut microbiota-
mediated conversion into metabolites called urolithins [31, 36]. Urolithins [36] are microbial
metabolites derived from EA or ellagitannins by commensal bacteria [37] and are dibenzo-
pyran-6-one derivatives with different hydroxyl group substitutions. If appropriate gut micro-
biota is present in healthy individuals, urolithins can reach up to micromolar concentrations in
the plasma of humans [33] as well as in different target tissues of animal models [38–40] with-
out any toxicity. Among urolithins, Urolithin A (UA; 3,8-dihydroxybenzo[c]chromen-6-one)
has been shown to influence the microbiota composition in rat models [38], but the signifi-
cance of these changes remain to be established. Basic pharmacodynamics studies of UA have
been established in both humans and mice models (reviewed by Epsin JC et al [31]). These
studies highlight that the concentration of UA reaches up to micromolar (μM) without display-
ing any toxic effects in vivo. For instance, upon consumption of pomegranate juice by humans,
peak plasma levels of UA could reach from 14 to 40 μM but with a large individual-variations
[33, 41]. Such variation could be due to that the bacteria responsible for urolithins production
may or may not be present in all individuals. Recently, Selma et al identified the mono cultured
T
bacteria (Gordonibacter urolithinfaciens and Gordonibacter pamelaeae DSM 19378 ) that are
responsible for metabolizing the EA to produce luteic acid, UroM-5, UroM-6 and UroC [37].
However, these cultured bacteria are incapable of producing the downstream products, UroA
(
UA) and UroB. Thus, several efforts are now underway to determine the bacterial phyla or
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
2 / 21

Urolithin A Controls Neutrophilic Inflammation
group of bacteria responsible for production of UroA and UroB, which can potentially serve as
probiotics.
Myeloperoxidase (MPO) is a 150-kDa protein belonging to the heme peroxidase superfam-
ily that includes eosinophil peroxidase, lactoperoxidase (LPO), thyroid peroxidase, and prosta-
glandin H synthase [42]. It is predominantly expressed in neutrophils and mediates the
-
generation of hypochlorus acid from hydrogen peroxide (H O ) and chloride anion (Cl ) dur-
2
2
ing respiratory burst of neutrophils. Heme group is critical to catalyze these actions [43].
MPO-produced hypochlorous acids are cytotoxic and thus are utilized in killing bacteria by
neutrophils as part the host innate defense mechanism [44, 45]. However, they also contribute
to tissue damage and perpetuation of inflammatory disorders including inflammatory bowel
disease (IBD) [46–49]. Accordingly, there is significant interest in developing MPO inhibitors
as potential strategy to mitigate the adverse effects of MPO during inflammation. To date, sev-
eral naturally occurring polyphenolic compounds have been reported to act as inhibitors of
MPO such as harmala alkaloids [50] and epigallocatechin-3-gallate (EGCG) [51].
The aim of the study is to determine the potential beneficial anti-inflammatory and peroxi-
dase inhibitory activities of UA compared to EA in in vitro and in vivo models. Here, we exam-
ined the effects of EA and UA on activities of MPO/LPO, interdependence of Ferric iron and
host neutrophil gelatinase-associated lipocalin (human NGAL) and its murine ortholog lipoca-
lin 2 (Lcn2). We also tested the efficacy of EA and UA in phorbol 12-myristate 13-acetate
(
PMA)-induced ear edema model. Altogether, our findings provide insights into interplay
between microbiota-derived phytometabolites and host NGAL/Lcn2 in the complex regulation
of heme peroxidases.
Materials and Methods
Materials
Mouse recombinant (rec)-Lcn2 was obtained from Cell Signalling and human rec-NGAL was
acquired from R&D Systems; both of which are free from endotoxin, siderophore, and iron.
Human MPO was procured from R&D Systems (Minneapolis, MN). EGCG, PMA, ferric chlo-
ride, PIPES, agar, and H O were procured from Sigma-Aldrich (St. Louis, MO). Bovine milk
2
2
LPO was purchased from Worthington Biochemical Corp (Lakewood, NJ). Chrome Azurol S
was purchased from Acros Organics. Guaiacol (2-methoxyphenol) was obtained from Alfa
Aesar (Ward Hill, MA).
Synthesis of UA
In a 500 ml round bottom flask, a solution of 2-bromo-5-methoxy benzoic acid (10gm, 0.043
moles) and AlCl (17.26 gm, 0.129 moles) in chlorobenzene (230 ml) was added and the reac-
3
tion was refluxed for 16 hrs at 131°C. The product obtained was extracted using ethylacetate
and concentrated using rotary evaporator. In a two necked round bottom flask, the demethyl-
ated product (2-bromo-5-hydroxy benzoic acid) obtained in reaction 1 (8.7 gms, 0.04 moles)
along with resorcinol (4.414 gm, 0.04 moles), sodium hydroxide (4 gm, 0.10 moles) was mixed
with water (45.5 ml) and reaction was refluxed for 2 hrs at 100°C. To the above mixture, 10%
w/v CuSO (17 ml) was added and refluxed for another 2 hrs. Crude product was purified by
4
column chromatography. The desired compound was eluted with a solvent mixture of hexane:
ethyacetate (50:50) followed by recrystallization in ethylacetate to ensure high purity. The puri-
fied UA (1 g) was concentrated and characterized by TLC, NMR spectroscopy, mass spectros-
copy and HPLC (S1 Scheme).
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
3 / 21

Urolithin A Controls Neutrophilic Inflammation
MPO and LPO in vitro Assay
Stock solutions of EA (10 mM) and UA (100 mM) were prepared in Dimethyl sulfoxide
DMSO, sigma) and subsequent dilutions were prepared in PBS. MPO and LPO assays are
(
based on the principle that peroxidase oxidizes guaiacol (2-methoxyphenol) in the presence of
H O to a chromophore 3,3’-dimethoxy-4,4’ biphenylquinone [52]. The change in absorbance
2
2
at 470 nm was measured per minute intervals over a period of 10 min. The reactions were exe-
cuted at pH 6.0 and 25°C in 96-well plates (Corning, NY) in triplicate using appropriate vehi-
cles and buffer controls throughout the study. One unit of MPO activity was defined as the
amount that increases absorbance at 470 nm by one per minute at 25°C, calculated from the
initial rate of reaction with the use of guaiacol as the substrate. Bovine milk LPO and Human
MPO were reconstituted with 0.1 mol/L potassium phosphate buffer, pH 6.0 and stored at
-
80°C. MPO (12.5 μg/ml, final reaction concentration) or LPO (25 μg/ml, optimum concentra-
tion) were pre-incubated with different concentrations of EA and UA (0–100 μM) with or
without mLcn2/hu NGAL or iron (FeCl ) for 5 min at room temperature in 20 μl reaction mix-
3
-
3
ture. The reaction was initiated on the addition of 30 μL of H O (6.7x10 %) and 50 μL of 100
2
2
mmol/L guaiacol (prepared in 0.1 mol/L potassium phosphate buffer). The change in absor-
bance at 470 nm was recorded per minute intervals over a period of 10 min.
CAS agar Assay
Chrome Azurol S (CAS) agar plates were prepared according to procedure described by
Schwyn and Neilands [53]. The principle of CAS assay is CAS remains blue in color when com-
plexed with iron but turns into orange color halo when iron is chelated by iron chelators. In
CAS agar plate, formation of orange halos indicates the iron chelation properties of the given
compound. Briefly, 2 μL of EA or UA mixed with or without FeCl at indicated concentrations
3
were placed on CAS plate and monitored for orange-color halo formation. The intensity of
halo formation is directly proportional to the concentration of chelated iron. EGCG (Sigma-
Aldrich) was used as a positive control [51].
CAS liquid assay
CAS reagent was prepared according to the procedure described by Payne in 1994 [54]. Briefly,
EA or UA (0–100 μM, 100 μl) and EGCG (positive control) were incubated with CAS reagent
(
6
100 μl) for 20 min in a 96 well plate at room temperature and absorbance was monitored at
30 nm. The percent iron chelation was calculated from the absorbance difference against
blank (vehicle).
Spectral Analysis
To perform spectral analysis, LPO (1.0 mg/ml) was reconstituted in 500 μl of 0.1 mol/l phos-
phate buffer (pH 6.0) and basal spectra were recorded at 412 nm for freshly reconstituted LPO.
The reaction was initiated when 30 μM H O was added to LPO, followed by addition of either
2
2
EA (50 μM), UA (50 μM) or vehicle. Spectra were recorded throughout the reaction at 300 to
00 nm every 3 seconds using CARY50BIO UV-Visible Spectrophotometer. Each spectrum
5
represents an average of six scans. All reaction concentrations above represent final system
concentrations.
Isolation of bone marrow derived neutrophils (BMDNs)
Murine bone marrow cells from WT C57BL/6 mice were isolated and neutrophils were sepa-
rated by density gradient centrifugation as described by Swamydas and Lionakis [55]. BMDNs
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
4 / 21

Urolithin A Controls Neutrophilic Inflammation
were prepared using Histopaque gradient (Sigma) method [55] and obtained >95% pure and
>
99% viable neutrophils, which was confirmed with flow cytometry.
Nitroblue tetrazolium (NBT) reduction assay
5
BMDN cells (2x10 cells/well) were seeded on a 96 well in triplicates with a working concentra-
tion of NBT (1 mg/mL) with and without PMA (50 nM) in presence of EA or UA (50 μM) and
then incubated at 37°C for 3 hrs. Images of cells were taken after incubation and a minimum of
1
00 cells were observed in each well for NBT-positive cells (%). The cells were fixed using 200
proof ethanol at -20°C for 15 minutes followed by two washes in 70% ethanol. Wells were
allowed to dry and 140 μL of KOH (2M) was added to lyse all cells followed by 160 μL of
DMSO to solubilize the formazan. After homogenization of the contents in the wells, the absor-
bance was read at 620 nm [56].
PMA-induced ear edema
All the animal protocols were approved by IACUC at University of Louisville, Louisville, KY.
C57BL/6 mice (6–8 weeks old) were purchased from Jackson laboratories. Acute PMA-induced
ear edema was performed according to method described previously [57]. Briefly, mice were
divided into 4 groups (n = 5) viz. vehicle (10% glucose), UA (40 mg/kg body weight), EA (40
mg/kg body weight) and indomethacin (10 mg/kg body weight); indicated treatments were
delivered orally (100 μl) 2 hrs before the application of PMA. PMA (4 μg/ear in 20 μL acetone)
was applied to inner surface on right ear of each mouse while left ear of each mouse received
vehicle (20 μL acetone) on inner surface. At six hours post-application of PMA, animals were
sacrificed by cervical dislocation and 6 mm diameter disc from each ear was removed using
metal punch. The tissues were weighed and ear edema weight was calculated by subtracting the
weight of the left ear from the right ear (treatment). Percent inhibition was calculated and
expressed as decrease in weight with respect to control. Tissue samples obtained from each
mouse were also assessed for MPO activity using Bradley et al method [58]. Briefly, tissue (6
mm) was homogenised in 50 mM phosphate buffer containing 0.5% hexadecyl trimethylam-
monium bromide using polytron homogenizer (Ultra-turrax T8). Samples were centrifuged
after three freeze-thaw cycles (-80°C and 37°C) at 5000 rpm for 20 min at 4°C. Supernatant
was used to measure MPO activity. Briefly, 10 μL of sample was mixed with 190 μL of 50 mM
phosphate buffer (pH 6.0) containing 0.167 mg/mL O-dianisidine and 0.005% H O . The
2
2
change in absorbance was measured at 460 nm using Synergy HT spectrophotometer (Biotek
Instruments Inc.) MPO activity results were represented as units per 6 mm of tissue. One unit
of MPO activity was defined as that degradation of 1 mM peroxide per minute at 25°C.
Statistical Analysis
All experimental results were reproduced in at least three independent experiments performed
in triplicates. All values in the results are expressed as mean ± SEM. The significance of differ-
ence between different groups was determined by unpaired Student t-test in case of two groups.
P-value less than 0.05 were considered statistically significant. GraphPad Prism version 6.0
(
GraphPad Software Inc., La Jolla, CA) was used to calculate statistical significance.
Results
Synthesis and characterization of Urolithin A (UA)
UA has been synthesized from 2-bromo-5-methoxy benzoic acid in two steps as described in
Methods section. The purified UA was obtained as slight yellow color solid, which was
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
5 / 21

Urolithin A Controls Neutrophilic Inflammation
characterized using NMR spectroscopy, mass spectroscopy and HPLC (S1 Scheme, S1 and S2
Figs). High performance liquid chromatography (HPLC, S3 Fig): HPLC was performed to
quantify the amount of Urolithin-A. The mobile phase consisted of 50% of Acetonitrile and
5
0% of Water:Formic acid (99:1).The solvent used to dissolve the compound was tetrahydrofu-
ran with an injection volume of 20 μl. The flow rate through the CAPCELL PAK C18 Column
4.6mm× 250mm, SHISEIDO) was 1 ml/min for 10 minutes with post run time of 50 seconds
(
and column temperature being 30.0°C. The UV detection wavelength for the drug was 280nm.
Urolithin-A was shown RT of 4.1 min (S3 Fig).
UA inhibits MPO and LPO in dose and time dependent manner
EA and their microbial metabolites have been shown to have anti-inflammatory and anti-oxi-
dative activities [31], although their underlying molecular mechanisms are not completely
understood. Here, we investigated the effects of parent compound, EA and its microbial metab-
olite, UA on the pro-oxidant activities of MPO and LPO. As shown in Fig 1, EA and UA signif-
icantly reduced the MPO and LPO activities in both dose (Fig 1A and 1B) and time dependent
manner (Fig 1C and 1D). Most importantly, UA at 10 μM concentration potently inhibited
MPO activity, whereas EA show an approximately two-fold reduced inhibitory activity at this
concentration. Our analysis suggested that UA is 10-times more effective than EA, given that
1
0 μM of UA could inhibit MPO activity by 60% whereas 100 μM EA was required to achieve
equivalent level of inhibition. Similarly, UA also inhibited the activity of LPO, which is another
heme-containing peroxidase (Fig 1B and 1D). It is intriguing that UA potently inhibited MPO
activity within a minute after addition to the reaction mixture, whereas EA-mediated inhibition
was relatively slower that gradually reaches its optimal inhibitory effect at 6 min after initiation
of MPO activity (Fig 1C). The inhibitory potency of UA was also observed to much stronger
towards LPO than MPO (Fig 1D).
UA fails to chelate ferric iron
Since many plant-derived polyphenols (i.e. epigallocatechin-3-gallate or EGCG) are known to
bind iron [59], therefore we next asked whether iron-binding could affect the peroxidase inhib-
itory activity of EA and UA. Accordingly, we employed the chrome azurol S (CAS) assay to test
for the ability of EA and UA in chelating iron, using EGCG as the positive control. As shown
Fig 2A, CAS agar plate assay demonstrated that EA and EGCG are both capable of binding
iron, whereas UA failed to chelate iron. This could be attributed the presence of catechol group
(
2-OH groups one phenyl group next to each other) on EA responsible for iron chelation,
which is absent in UA. We also confirmed these results using CAS liquid assays and repre-
3+
sented as percent Fe chelation (Fig 2B). Our spectral analysis of UA further confirmed that it
is completely free from iron (data not shown).
Ferric iron modestly counter-regulates the peroxidase inhibitory activity
of UA, but completely abrogates the inhibitory activity of EA
We previously reported that iron-free, but not iron-saturated EGCG could potently inhibit the
activity of heme peroxidases [51]. In a similar fashion, we observed that adding EA and ferric
iron at molar ratio of 1:3 completely abrogated the ability of EA to inhibit the activity of MPO
+
(
Fig 3A). However, the increased molar concentration of UA:Fe3 from 1:0 to 1:1 only mod-
estly mitigated UA inhibitory activity, whereas the increment from 1:1 to 1:3 did not result in
further significant reduction of MPO activity (Fig 3B). Similar results were observed, when we
repeated the experiment on LPO activity (Fig 3C and 3D). The greater susceptibility of EA
3+
than UA inhibitory activity to be abrogated by Fe may be due to EA’s ability to chelate iron,
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
6 / 21

Urolithin A Controls Neutrophilic Inflammation
Fig 1. EA and UA inhibit MPO and LPO activity in dose dependent manner: EA or UA (0–100 μM) was pre-incubated at the indicated final
-
3
concentrations with MPO (12.5 μg/ml) or LPO (25 μg/ml) for 5 min in 20 μl reaction volume before addition of 30 μl of H
2 2
O (6.7x10 %) and
5
0 μl of 100 mmol/L guaiacol. Bar graph represent EA and UA mediated dose-dependent inhibition of MPO (A) and LPO (B) activity. Line graph
represents EA (50 μM) and UA (50 μM) mediated inhibition of MPO (C) and LPO (D) activity with time. Assays were carried out in 96-well plates in
triplicates with appropriate vehicles/buffers. Results are representative of three independent experiments and are expressed as mean ± SEM.
*p < 0.05.
doi:10.1371/journal.pone.0156811.g001
whereas UA does not bind iron. These findings implicate a unique advantage of UA over EA as
3+
a heme peroxidase inhibitor that could withstand Fe counter-regulatory effects.
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
7 / 21

Urolithin A Controls Neutrophilic Inflammation
3+
Fig 2. EA, but not UA, can chelate iron. (A) EA or UA (1–10 mM) were pre-incubated with or without Fe at indicated molar ratio and then 2 μl
of the reaction mixture was applied on Chrome azurol S (CAS) plate. Formation of orange halo indicated chelation of iron in the CAS plate.
EGCG and FeCl
3
Á6H
2
O were used as positive and negative controls, respectively. In the liquid CAS assay, EA or UA (0–100 μM, 100 μl) and
EGCG (positive control) was incubated with CAS reagent (100 μl) for 20 min and absorbance was monitored at 630 nm; % chelation was
calculated against blank. (B) Line graphs represent the % chelation of Fe by EA, UA and EGCG. Results are expressed as mean ± SEM.
Assays were performed in a 96-well plate in triplicates and are representative of three independent experiments. *p < 0.05.
3
+
doi:10.1371/journal.pone.0156811.g002
Innate immune protein lipocalin 2 mitigates the inhibitory heme
peroxidase activity of UA
The multifaceted innate immune protein murine Lipocalin 2 (Lcn2) and its human orthologue
NGAL have been demonstrated to protect MPO activity from being inactivated by bacterial
siderophore enterobactin [60] and EGCG [51]. Lcn2 are expressed in neutrophils and play an
important role in limiting bacterial growth by sequestering iron-containing siderophores.
Expression of Lcn2 as well as MPO is significantly increased during intestinal inflammation
[
61, 62]. Herein, we examined whether presence of murine Lcn2 and human NGAL could have
any influence on UA-mediated inhibition of MPO and LPO activity. As shown in Fig 4A and
C, NGAL significantly reduced UA-mediated inhibitory activity of both MPO and LPO in a
4
dose dependent manner. The addition of NGAL to 10 μM UA at molar ratio of 1:1 reduced the
percent UA-mediated MPO inhibition from ~40% to ~10%, which translates to approximately
3
.5-fold loss of UA bioactivity. We observed similar mitigation of UA inhibitory effect on LPO
as well (from ~60% to ~17% inhibition) when NGAL was added to UA at 1:1 molar ratio. Simi-
lar to NGAL, mouse orthologue, Lcn2 also significantly mitigated UA heme peroxidase inhibi-
tory activity (Fig 4B and 4D). However, we were not able to perform similar analysis on EA
due to technical limitation i.e. 100 μM of EA are needed to achieve significant MPO/LPO inhi-
bition, but NGAL/Lcn2 are not readily supplied at amount feasible to achieve 1:1 ratio with
1
00 μM of EA. Our experiment with 10 μM EA with NGAL/Lcn2 at 1:1 ratio failed mitigate the
bioactivity of EA (data not shown) probably because EA bioactivity was already low (~15–
0%) and could not be mitigated further.
2
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
8 / 21

Urolithin A Controls Neutrophilic Inflammation
3
+
Fig 3. Fe bound EA, but not UA, failed to inhibit heme peroxidase activity: UA (10 μM) or EA (10 μM)
and indicated molar ratio of FeCl O were pre-incubated at room temperature with either MPO
Á6H
12.5 μg/ml) or LPO (25 μg/ml) for 5 min before the assay was initiated. Bar graphs represent inhibition of
3
2
(
3
+
3+
MPO activity (A) EA+ Fe and (B) UA+ Fe at indicated molar ratio. Bar graph represents inhibition of LPO
3
+
activity by (C) EA and (D) UA in presence of Fe at indicated molar ratio. Results are expressed as
mean ± SEM. Assays were performed in a 96-well plate in triplicates and are representative of three
independent experiments. *p < 0.05.
doi:10.1371/journal.pone.0156811.g003
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
9 / 21

Urolithin A Controls Neutrophilic Inflammation
Fig 4. Human NGAL and its murine orthologue Lcn2 inhibit UA-mediated MPO and LPO inhibition. UA
(
10 μM) and indicated molar ratio of NGAL/mLcn2 were pre-incubated at room temperature with either 12.5 μg/ml
MPO or 25 μg/ml LPO for 5 min before the assay was initiated. Bar graphs represent inhibition of MPO activity by
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
10 / 21

Urolithin A Controls Neutrophilic Inflammation
UA in the presence of (A) NGAL and (B) mLcn2 at indicated molar ratio. Bar graph represents inhibition of LPO
activity by UA in presence of (C) NGAL and (D) mLcn2. Results are expressed as mean ± SEM. Assays were
performed in a 96-well plate in triplicates and are representative of three independent experiments. *p < 0.05.
doi:10.1371/journal.pone.0156811.g004
UA and EA inhibit heme peroxidase by inactivating peroxidase-
catalysed reaction
LPO displays maximum absorbance (λmax) at 412 nm due to the presence of heme moiety
group in the enzyme (Fig 5A). To determine whether UA or EA interacts with heme group of
LPO, we recorded the absorbance spectra of LPO in the presence of UA or EA. However, the
addition of UA or EA did not result in any changes in the spectra of LPO (data not shown),
indicating that mechanism of inhibition by UA/EA does not involve heme iron-binding. Next,
we tested whether UA/EA have effect on LPO-H O spectral properties. We knew that, upon
2
2
3
+
the addition of H O to LPO, the heme iron (Fe ) of LPO would interacts with H O and pro-
2
2
2 2
duce redox intermediate called oxoiron with λmax at 430 nm (Fig 5B). The addition of EA (Fig
C) or UA (Fig 5D) reverted the LPO-H O spectra (λmax) from 430 nm back to 412 nm.
5
2
2
These observations indicated that these compounds reverted the redox reaction and restored
3
+
the native Fe state of heme of LPO. Intriguingly, the UA-mediated spectral shift was notice-
ably more rapid and faster than the slower spectral shift mediated by EA (Fig 5E and 5F).
UA inhibits PMA-induced generation of reactive oxygen species (ROS)
in neutrophils
The phorbol myristate acetate (PMA) is a well-known inducer of oxidative stress in neutrophils
via induction of ROS production catalyzed by NADPH-oxidase. Hence, we next asked whether
UA and EA could inhibit the ROS production in PMA-stimulated neutrophils by employing
the nitroblue tetrazolium (NBT) reduction assay to detect the production of intracellular ROS.
Accordingly, we observed that UA significantly mitigated PMA-induced NBT formazan pro-
duction in neutrophils, suggesting that UA could also inhibits ROS production (Fig 6A and
6
B). In contrast, EA failed to block ROS production in PMA-treated neutrophils. Intriguingly,
EA alone was sufficient to induce ROS production in neutrophils even without PMA stimula-
tion, but this was not the case for UA. We postulated that EA may have pro-oxidant effects in
addition to its anti-oxidant properties, which may require further mechanistic study. Nonethe-
less, our findings herein seem to support the notion that UA may be a superior phytoceutical
agent than EA not only in inhibiting MPO and LPO, but also broadly inhibit other pro-oxida-
tive enzymes (i.e. NADPH oxidase).
UA mediates better protection than EA in mitigating PMA-induced ear
edema and MPO activity
To examine the in vivo effects of UA and EA, we next tested for their efficacy in treating PMA-
induced ear edema in mice. In this acute inflammation model, the severity of disease is
reflected by the increased ear edema weight and elevated MPO activity in ear tissue. As shown
Fig 7A, mice pre-treated with UA displayed significantly reduced PMA-induced ear edema by
4
3% when compared to vehicle-treated mice. The extent of protection against PMA-induced
ear edema mediated by UA is almost comparable to indomethacin (a positive control) which
markedly reduced ear edema by 47.5%. Unlike UA, pretreatment with EA failed to provide sig-
nificant reduction on PMA-induced ear edema, suggesting that UA display superior efficacy
than EA in mitigating acute inflammation. Nevertheless, both UA and EA significantly inhib-
ited the MPO activity induced by PMA, but the inhibition was mediated at a greater extent by
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
11 / 21

Urolithin A Controls Neutrophilic Inflammation
Fig 5. EA and UA avert the heme peroxidase-catalysed reaction. To perform spectral analysis, LPO (1
mg/ml, in 0.1M phosphate buffer) + H
2 2
O (30 μM) was incubated with either 50 μM of EA or UA. Spectra were
recorded at 300 to 500 nm at every 3 seconds. Each spectrum represents an average of six scans. Image
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
12 / 21

Urolithin A Controls Neutrophilic Inflammation
represents (A) LPO alone, (B) LPO + H
2 2 2 2 2 2 .
O , (C) LPO + H O + EA and (D) LPO + H O + UA Arrows
designate the direction of spectral changes over time on the initiation of the reaction. Kinetics of spectral
2 2
changes were recorded upon addition of (E) EA or (F) UA or vehicle to LPO-H O reaction. Results are
representative of three independent experiments.
doi:10.1371/journal.pone.0156811.g005
UA than EA. Indomethacin also decreased the MPO activity (Fig 7B). Representative H&E
images of ear edema further suggest decreased inflammatory cells in UA-treated animals com-
pared to EA treatment or vehicle (Fig 7C). H&E images also suggest that UA treatment also
reduced swelling (epidermis thickness) of ear caused by PMA treatment.
Discussion
Polyphenols-rich fruits such as berries and pomegranate have been extensively investigated for
their beneficial effects in the prevention of several human diseases. However, the results across
these studies are not consistent, possibly due to the large variation in the gut microbiota and
their metabolites which greatly influences their bio-potency. The gut microbial dysbiosis
(
imbalance in microbial population) especially in gastrointestinal tract-related disorders such
as IBD presents yet another major challenge in designing optimal dietary intervention. Several
strategies have been sought to improve/alter the gut microbiota through prebiotics, probiotics,
antibiotics and fecal microbial transplantations (FMT) to treat patients with IBD [63, 64]. The
use probiotics and FMT to treat pouchitis and recurrent Clostridium difficile infections were
highly successful in most of the cases [65]. Probiotics such as Bifidobacteria and Lactobacillus
have been reported to have some beneficial effects in maintaining remission in IBD patients
[66, 67]. We postulate that direct usage of the active metabolites will be beneficial in preventing
several chronic disorders and will allow to overcome inter-individual variations in gut micro-
biota. Bacterial-derived metabolites such as short chain fatty acids (SCFAs), particularly buty-
rate, have been demonstrated to have beneficial and preventive effects in animal models of
autoimmune, IBD and some cancers [68]. Recently, Rusdensky AY’s group demonstrated that
metabolites (butyrate) produced by commensal bacteria promote peripheral regulatory T-cell
generation [69] and Medzhitov R’s group showed that butyrate regulates intestinal macrophage
function via histone deacetylase (HDAC) inhibition [70]. These studies are encouraging to
identify novel biological actions, targets and molecular mechanisms of microbial metabolites in
preventive and therapeutic settings of several disorders.
Here, we focused on examining one of the microbial metabolite UA for their potency in
inhibiting the activity of heme peroxidases (i.e. MPO and LPO). MPO is a hemoprotein
expressed in polymorphonuclear neutrophils and macrophages; its production are significantly
increased in IBDs [62] and other inflammatory disorders [71]. The release of MPO by activated
immune cells promote inflammation, whereas inhibition of MPO can significantly protects
from inflammation-mediated tissue damage in IBDs. To the best of our knowledge, there are
currently no safe MPO inhibitors that are available to reduce the severity of MPO-driven
inflammation. Therefore, the use of naturally available dietary and microbial metabolites to
modulate MPO activity present an attractive approach in treating inflammatory disorders. In
this study, we demonstrate that physiological concentrations of UA significantly inhibited the
activity of MPO and LPO. It is pertinent to highlight that microbial-derived UA is a more
potent inhibitor than its parent compound EA, indicating collegial nature of microbiota and its
metabolites to protect from increased inflammation. EA contains catechol group (2 OH groups
adjacent on phenyl group), which are capable of chelating iron. Interestingly, gut microbiota
metabolizes EA by series of enzymatic reactions and removes these catechol groups from EA to
generate UA. Such modification provides several notable advantage to the gut microbiota: (1)
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
13 / 21

Urolithin A Controls Neutrophilic Inflammation
Fig 6. UA attenuated ROS production in PMA-stimulated bone marrow-derived neutrophils (BMDNs).
5
To quantify the superoxide production in BMDN cells, (2x10 /well) were added to a 96 well in triplicates with
1mg/mL NBT in presence or absence of PMA (50 nM) with and without EA or UA (50 μM) and then incubated
at 37°C for 3 hrs. NBT assay was performed and absorbance was recorded at 620 nm. (A) Images illustrate
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
14 / 21

Urolithin A Controls Neutrophilic Inflammation
formazan production (NBT reduction, blue deposition) in BMDNs at 40X magnification. (B) Bar graphs
represent the levels of formazan detected in the NBT reduction assay. Results are expressed as
mean ± SEM. Assays were performed in a 96-well plate in triplicates and are representative of three
independent experiments. *p < 0.05.
doi:10.1371/journal.pone.0156811.g006
it removes iron-binding EA from competing with bacterial iron acquisition, and (2) augments
the inhibitory activity of UA which, unlike EA, could not be suppressed by iron-binding.
Iron deficiency anaemia is one of major problem that is commonly associated with IBD.
Indeed, one third of IBD patients were reported to suffer from recurrent anaemia. Unfortu-
nately, oral iron treatment is limited by poor absorption, intolerance, and induction of oxida-
tive stress at the site of bowel inflammation. Therefore, presence of bacteria that is responsible
(
currently unknown) for production UA from EA is beneficial and potentially lead to increase
free iron and decrease in anaemic state in colonic disorders, including IBDs. In this study, we
demonstrated that UA lacked the ability to chelate iron, unlike EA and EGCG that display
iron-binding properties. We envision that the therapeutic use of EA may not be ideal since its
iron-chelating property may further aggravate iron deficiency anaemia associated with IBD. In
this regard, we postulate that UA may be a better therapeutic metabolite than EA, given the
superior peroxidase inhibitory activity and non-iron binding properties of UA.
The potency of UA in inhibiting the activity of heme peroxidase prompted us to investigate
the potential underlying mechanisms that are involved. In this study, we performed spectral
analysis using LPO as our model heme peroxidase; however, we could not employ MPO in our
spectral analysis due to technical limitation (i.e. amount supplied is inadequate). Heme peroxi-
dase (e.g. LPO) displays absorbance spectra with λmax at 412 nm due to the presence of its
heme moiety group. The addition of H O to LPO would result in the formation of the peroxi-
2
2
dase radical intermediate oxoiron with λmax at 430 nm. Interestingly, the treatment with UA
or EA prematurely inactivates the peroxidase-catalyzed reaction and reversed the oxoiron
group to its normal native state. The inactivation of peroxidase activity by UA and EA suggests
that these compounds are capable of negating the production of hypohalous acid by LPO and
potentially MPO as well. This outcome could be possibly be attributed to the donation of elec-
trons by UA to the oxoiron state of the heme and thus, revert to its native state. The UA-medi-
ated inhibition of MPO may be beneficial in mitigating hypohalous acid-mediated tissue
damage in the intestines during increased inflammatory conditions.
Lipocalin (Lcn2) and its human ortholog NGAL sequester iron-containing siderophore as
an innate immune mechanism to limit the growth of bacteria, especially during infection or
inflammation. Accordingly, the mice lacking Lcn2 are more susceptible to bacterial infection
compare to wild type mice [72]. Herein, we observed that 10 μM of UA inhibits approximately
4
0% of MPO activity. Interestingly, in the presence of Lcn2/NGAL, the inhibitory activity of
UA is significantly mitigated (less than 10% inhibition of MPO), suggesting that UA can be
sequestered by Lcn2 or NGAL. The findings that Lcn2/NGAL preserves the activity of MPO
from being inactivated by UA are reminiscent of our previous studies with EGCG and bacterial
enterobactin (Ent) [51, 60]. Similar to UA, EGCG and Ent are potent MPO inhibitors that also
loses their efficacy upon complexing with Lcn2/NGAL [51, 60]. It is possible that Lcn2/NGAL
system is evolutionarily designed to selectively remove the iron-binding siderophore and poly-
phenols so that immune system can clear the bacterial infections. Future studies on UA-based
therapeutics may need to consider the counter-regulatory function of Lcn2/NGAL when opti-
mizing the doses UA to be given to IBD patients.
•−
2
PMNs produce a variety of reactive oxygen species (ROS), including superoxide anion (O ),
•
hydrogen peroxide (H O ), hydroxyl radical ( OH), and hypochlorous acid (HOCl) upon stimu-
2
2
lation by soluble agonists, such as phorbol ester, chemotactic peptides, and calcium ionophore.
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
15 / 21

Urolithin A Controls Neutrophilic Inflammation
Fig 7. UA treatment reduces PMA-induced ear edema and MPO activity. Mice (n = 5) were orally gavaged with vehicle
control (10% glucose), UA (40 mg/kg body weight), EA (40 mg/kg body weight) and indomethacin (10 mg/kg body weight) at
2
hrs prior to applying PMA to right ear and acetone (control) to the left ear. At six hrs post application of PMA, animals were
sacrificed by cervical dislocation and (A) weight of edema and (B) MPO activity was evaluated as described in material and
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
16 / 21

Urolithin A Controls Neutrophilic Inflammation
method section. Results are expressed as mean ± SEM. *, ** and *** indicates p value < 0.05, 0.01 and 0.001, respectively
compared to vehicle group. (C) Representative H&E images of ear edema at 100x magnification (left) and 400x magnification
(
right) indicate decreased PMA induced inflammation i.e., infiltration of inflammatory cells in UA treated animals compared to
vehicle or EA treated animals. The images were captured using Aperio Imagescope and scale bars on 100x and 400x
magnifications indicate 300 μm and 60 μm respectively.
doi:10.1371/journal.pone.0156811.g007
The phagocyte activation leads to increase in the production of superoxide anion leading to oxi-
dative burst. In general, stimulation of neutrophils by PMA increases the ROS formation, which
can be quantified by NBT assay. In this study, we further demonstrated that UA treatment could
mitigate PMA-induced ROS formation in neutrophils (in vitro), but such protective effect was
not observed with EA. Instead, we found that EA alone could induce ROS formation, suggesting
that EA, but not UA, may have pro-oxidant properties that need to be further investigated. Fur-
thermore, we confirmed these observations in in vivo model, where oral treatment of UA signifi-
cantly reduced PMA induced ear edema and MPO activity suggesting its potential role as an
anti-inflammatory agent. In support of these observations including our unpublished data, it was
demonstrated that UA is able to markedly reduce carrageen-induced paw edema as well as LPS
mediated anti-inflammatory activities in other models [73].
In summary, our studies demonstrate that UA is a potent inhibitor of MPO compared to its
parent compound, EA. The inability of UA to bind iron allows it to retain its peroxidase-inhibi-
tory activity in the presence of ferric iron, whereas EA loses its bioactivity significantly upon
binding to iron. However, the innate immune protein NGAL could reverses the UA-mediated
inhibition of heme peroxidase activity, implicating its regulation by host-defense and inflam-
matory activities. Finally, we have demonstrated UA potent inhibitory activities on PMA
induced ROS production as well as significant reduction of PMA-induced ear edema in a
mouse model. These studies form strong evidence that gut microbiota-derived active metabo-
lites are critical in controlling inflammatory pathways.
Supporting Information
S1 Scheme. Schematic diagram of Urolithin A (UA) synthesis.
(
TIF)
1
1
S1 Fig. H-NMR spectra of Urolithin A (UA). H-NMR DMSO-d6: 800MHz: δ: 10.22 (1H,
s), 10.15 (1H, s), 8.09–8.07 (1H, d, J = 12), 8.00–7.99 (1H, d, J = 12), 7.50 (1H, s), 7.31–7.30
(
(
1H, m), 6.80–6.78 (1H, m), 6.72 (1H, s).
TIF)
1
3
13
S2 Fig. C-NMR spectra of Urolithin A (UA). C-NMR: DMSO-d6: 800MHz: δ: 160.60,
58.53, 156.93, 150.88, 126.94, 124.14, 123.77, 123.54, 120.15, 113.52, 113.02, 109.82, 102.83.
TIF)
1
(
S3 Fig. HPLC spectra of Urolithin A (UA).
TIF)
(
S4 Fig. Potential EA binding mode to iron.
TIF)
(
Author Contributions
Conceived and designed the experiments: VRJ MV-K PKV BH. Performed the experiments: PS
BSY RS BC. Analyzed the data: VRJ MV-K PS RS PKV. Contributed reagents/materials/analy-
sis tools: VRJ MV-K PKV. Wrote the paper: VRJ MV-K PS PKV RS.
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
17 / 21

Urolithin A Controls Neutrophilic Inflammation
References
1.
O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006; 7(7):688–93. doi: 10.
038/sj.embor.7400731 PMID: 16819463; PubMed Central PMCID: PMCPMC1500832.
1
2.
Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, et al. The gut microbiota and
host health: a new clinical frontier. Gut. 2016; 65(2):330–9. doi: 10.1136/gutjnl-2015-309990 PMID:
26338727; PubMed Central PMCID: PMCPMC4752653.
3.
Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nature
reviews Gastroenterology & hepatology. 2012; 9(10):577–89. doi: 10.1038/nrgastro.2012.156 PMID:
2
2945443.
Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;
0(3):859–904. doi: 10.1152/physrev.00045.2009 PMID: 20664075.
4.
5.
6.
9
Rutledge PJ, Challis GL. Discovery of microbial natural products by activation of silent biosynthetic
gene clusters. Nat Rev Microbiol. 2015; 13(8):509–23. doi: 10.1038/nrmicro3496 PMID: 26119570.
Tomkovich S, Jobin C. Microbiota and host immune responses: a love-hate relationship. Immunology.
2016; 147(1):1–10. doi: 10.1111/imm.12538 PMID: 26439191; PubMed Central PMCID:
PMCPMC4693877.
7
.
.
Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1):121–41.
doi: 10.1016/j.cell.2014.03.011 PMID: 24679531; PubMed Central PMCID: PMCPMC4056765.
8
Belkaid Y, Naik S. Compartmentalized and systemic control of tissue immunity by commensals. Nature
immunology. 2013; 14(7):646–53. doi: 10.1038/ni.2604 PMID: 23778791; PubMed Central PMCID:
PMCPMC3845005.
9.
Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, et al. Microbial dysbiosis in
colorectal cancer (CRC) patients. PloS one. 2011; 6(1):e16393. doi: 10.1371/journal.pone.0016393
PMID: 21297998; PubMed Central PMCID: PMC3029306.
1
1
1
0. Schwabe RF, Jobin C. The microbiome and cancer. Nature reviews Cancer. 2013; 13(11):800–12. doi:
10.1038/nrc3610 PMID: 24132111.
1. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome
Med. 2011; 3(3):14. Epub 2011/03/12. doi: 10.1186/gm228 PMID: 21392406.
2. Chung H, Kasper DL. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr
Opin Immunol. 2010; 22(4):455–60. Epub 2010/07/27. doi: 10.1016/j.coi.2010.06.008 PMID:
20656465.
13. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive
immune system? Science. 2010; 330(6012):1768–73. Epub 2011/01/06. doi: 10.1126/science.
1195568 PMID: 21205662.
14. Kuczynski J, Costello EK, Nemergut DR, Zaneveld J, Lauber CL, Knights D, et al. Direct sequencing of
the human microbiome readily reveals community differences. Genome Biol. 2010; 11(5):210. Epub
2
010/05/06. doi: 10.1186/gb-2010-11-5-210 PMID: 20441597; PubMed Central PMCID: PMC2898070.
5. Arthur JC, Jobin C. The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis.
011; 17(1):396–409. Epub 2010/09/18. doi: 10.1002/ibd.21354 PMID: 20848537.
1
1
2
6. Candela M, Guidotti M, Fabbri A, Brigidi P, Franceschi C, Fiorentini C. Human intestinal microbiota:
cross-talk with the host and its potential role in colorectal cancer. Crit Rev Microbiol. 2011; 37(1):1–14.
Epub 2010/09/30. doi: 10.3109/1040841X.2010.501760 PMID: 20874522.
1
1
1
7. Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Ramey RR, Bircher JS, et al. Evolution of mammals
and their gut microbes. Science. 2008; 320(5883):1647–51. Epub 2008/05/24. doi: 10.1126/science.
1155725 PMID: 18497261; PubMed Central PMCID: PMC2649005.
8. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut
microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027–31. Epub 2006/
12/22. doi: 10.1038/nature05414 PMID: 17183312.
9. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal
microbiota alters colitis-associated colorectal cancer susceptibility. PloS one. 2009; 4(6):e6026. Epub
2009/06/25. doi: 10.1371/journal.pone.0006026 PMID: 19551144; PubMed Central PMCID:
PMC2696084.
2
0. Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, et al. The
role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflamma-
tory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of
human diseases. Cell Mol Immunol. 2011; 8(2):110–20. Epub 2011/02/01. doi: 10.1038/cmi.2010.67
PMID: 21278760.
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
18 / 21

Urolithin A Controls Neutrophilic Inflammation
2
2
2
1. Mukherji A, Kobiita A, Ye T, Chambon P. Homeostasis in intestinal epithelium is orchestrated by the cir-
cadian clock and microbiota cues transduced by TLRs. Cell. 2013; 153(4):812–27. doi: 10.1016/j.cell.
2013.04.020 PMID: 23663780.
2. Alasalvar C, Bolling BW. Review of nut phytochemicals, fat-soluble bioactives, antioxidant components
and health effects. The British journal of nutrition. 2015; 113 Suppl 2:S68–78. doi: 10.1017/
S0007114514003729 PMID: 26148924.
3. Zhang HM, Zhao L, Li H, Xu H, Chen WW, Tao L. Research progress on the anticarcinogenic actions
and mechanisms of ellagic acid. Cancer Biol Med. 2014; 11(2):92–100. doi: 10.7497/j.issn.2095-3941.
2
014.02.004 PMID: 25009751; PubMed Central PMCID: PMCPMC4069806.
4. Heber D. Multitargeted therapy of cancer by ellagitannins. Cancer letters. 2008; 269(2):262–8. doi: 10.
016/j.canlet.2008.03.043 PMID: 18468784.
2
2
1
5. Girish C, Pradhan SC. Drug development for liver diseases: focus on picroliv, ellagic acid and curcu-
min. Fundam Clin Pharmacol. 2008; 22(6):623–32. doi: 10.1111/j.1472-8206.2008.00618.x PMID:
1
9049667.
6. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev.
008; 13(2):128–44. PMID: 18590349.
2
2
2
2
2
7. Bell C, Hawthorne S. Ellagic acid, pomegranate and prostate cancer—a mini review. The Journal of
pharmacy and pharmacology. 2008; 60(2):139–44. doi: 10.1211/jpp.60.2.0001 PMID: 18237460.
8. Banihani S, Swedan S, Alguraan Z. Pomegranate and type 2 diabetes. Nutr Res. 2013; 33(5):341–8.
doi: 10.1016/j.nutres.2013.03.003 PMID: 23684435.
9. Xu KZ, Zhu C, Kim MS, Yamahara J, Li Y. Pomegranate flower ameliorates fatty liver in an animal
model of type 2 diabetes and obesity. Journal of ethnopharmacology. 2009; 123(2):280–7. doi: 10.
1016/j.jep.2009.03.035 PMID: 19429373.
3
3
0. McFarlin BK, Strohacker KA, Kueht ML. Pomegranate seed oil consumption during a period of high-fat
feeding reduces weight gain and reduces type 2 diabetes risk in CD-1 mice. The British journal of nutri-
tion. 2009; 102(1):54–9. doi: 10.1017/S0007114508159001 PMID: 19079947.
1. Espin JC, Larrosa M, Garcia-Conesa MT, Tomas-Barberan F. Biological significance of urolithins, the
gut microbial ellagic Acid-derived metabolites: the evidence so far. Evidence-based complementary
and alternative medicine: eCAM. 2013; 2013:270418. doi: 10.1155/2013/270418 PMID: 23781257;
PubMed Central PMCID: PMCPMC3679724.
3
2. Cerda B, Llorach R, Ceron JJ, Espin JC, Tomas-Barberan FA. Evaluation of the bioavailability and
metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. European jour-
nal of nutrition. 2003; 42(1):18–28. doi: 10.1007/s00394-003-0396-4 PMID: 12594538.
3
3. Cerda B, Espin JC, Parra S, Martinez P, Tomas-Barberan FA. The potent in vitro antioxidant ellagitan-
nins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-diben-
zopyran-6-one derivatives by the colonic microflora of healthy humans. European journal of nutrition.
2004; 43(4):205–20. doi: 10.1007/s00394-004-0461-7 PMID: 15309440.
3
3
4. Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, Hingorani L, Derendorf H. Absorption, metabolism,
and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standard-
ized extract in healthy human volunteers. Journal of agricultural and food chemistry. 2006; 54
(
23):8956–61. doi: 10.1021/jf061674h PMID: 17090147.
5. González-Sarrías A, García-Villalba R, Núñez-Sánchez MÁ, Tomé-Carneiro J, Zafrilla P, Mulero J,
et al. Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy
volunteers after consumption of pomegranate extracts. Journal of Functional Foods. 2015; 19, Part
A:225–35. http://dx.doi.org/10.1016/j.jff.2015.09.019.
3
3
3
6. Cerda B, Periago P, Espin JC, Tomas-Barberan FA. Identification of urolithin a as a metabolite pro-
duced by human colon microflora from ellagic acid and related compounds. Journal of agricultural and
food chemistry. 2005; 53(14):5571–6. doi: 10.1021/jf050384i PMID: 15998116.
7. Selma MV, Beltran D, Garcia-Villalba R, Espin JC, Tomas-Barberan FA. Description of urolithin produc-
tion capacity from ellagic acid of two human intestinal Gordonibacter species. Food & function. 2014; 5
(
8):1779–84. doi: 10.1039/c4fo00092g PMID: 24909569.
8. Larrosa M, Gonzalez-Sarrias A, Yanez-Gascon MJ, Selma MV, Azorin-Ortuno M, Toti S, et al. Anti-
inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and
the effect of colon inflammation on phenolic metabolism. J Nutr Biochem. 2010; 21(8):717–25. doi: 10.
1016/j.jnutbio.2009.04.012 PMID: 19616930.
3
9. Espin JC, Gonzalez-Barrio R, Cerda B, Lopez-Bote C, Rey AI, Tomas-Barberan FA. Iberian pig as a
model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric
Food Chem. 2007; 55(25):10476–85. doi: 10.1021/jf0723864 PMID: 17990850.
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
19 / 21

Urolithin A Controls Neutrophilic Inflammation
4
0. Gonzalez-Sarrias A, Gimenez-Bastida JA, Garcia-Conesa MT, Gomez-Sanchez MB, Garcia-Talavera
NV, Gil-Izquierdo A, et al. Occurrence of urolithins, gut microbiota ellagic acid metabolites and prolifera-
tion markers expression response in the human prostate gland upon consumption of walnuts and
pomegranate juice. Mol Nutr Food Res. 2010; 54(3):311–22. doi: 10.1002/mnfr.200900152 PMID:
19885850.
4
4
4
1. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, et al. Pomegranate ellagitannin-
derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. Journal of
agricultural and food chemistry. 2007; 55(19):7732–7. doi: 10.1021/jf071303g PMID: 17722872.
2. Odobasic D, Kitching AR, Holdsworth SR. Neutrophil-Mediated Regulation of Innate and Adaptive
Immunity: The Role of Myeloperoxidase. J Immunol Res. 2016; 2016:2349817. doi: 10.1155/2016/
2349817 PMID: 26904693; PubMed Central PMCID: PMCPMC4745373.
3. Carpena X, Vidossich P, Schroettner K, Calisto BM, Banerjee S, Stampler J, et al. Essential role of
proximal histidine-asparagine interaction in mammalian peroxidases. The Journal of biological chemis-
try. 2009; 284(38):25929–37. doi: 10.1074/jbc.M109.002154 PMID: 19608745; PubMed Central
PMCID: PMCPMC2757993.
44. Heinecke JW, Li W, Francis GA, Goldstein JA. Tyrosyl radical generated by myeloperoxidase catalyzes
the oxidative cross-linking of proteins. The Journal of clinical investigation. 1993; 91(6):2866–72. doi:
10.1172/JCI116531 PMID: 8390491; PubMed Central PMCID: PMCPMC443356.
45. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxi-
dase, and bacterial killing. Blood. 1998; 92(9):3007–17. PMID: 9787133.
46. Davies MJ. Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention.
Journal of clinical biochemistry and nutrition. 2011; 48(1):8–19. doi: 10.3164/jcbn.11-006FR PMID:
2
1297906; PubMed Central PMCID: PMCPMC3022070.
7. Klebanoff SJ. Myeloperoxidase: friend and foe. Journal of leukocyte biology. 2005; 77(5):598–625. doi:
0.1189/jlb.1204697 PMID: 15689384.
4
4
1
8. Davies MJ, Hawkins CL, Pattison DI, Rees MD. Mammalian heme peroxidases: from molecular mecha-
nisms to health implications. Antioxidants & redox signaling. 2008; 10(7):1199–234. doi: 10.1089/ars.
2007.1927 PMID: 18331199.
4
5
5
9. Rees MD, Kennett EC, Whitelock JM, Davies MJ. Oxidative damage to extracellular matrix and its role
in human pathologies. Free radical biology & medicine. 2008; 44(12):1973–2001. doi: 10.1016/j.
freeradbiomed.2008.03.016 PMID: 18423414.
0. Bensalem S, Soubhye J, Aldib I, Bournine L, Nguyen AT, Vanhaeverbeek M, et al. Inhibition of myelo-
peroxidase activity by the alkaloids of Peganum harmala L. (Zygophyllaceae). Journal of ethnopharma-
cology. 2014; 154(2):361–9. doi: 10.1016/j.jep.2014.03.070 PMID: 24746482.
1. Yeoh BS, Aguilera Olvera R, Singh V, Xiao X, Kennett MJ, Joe B, et al. Epigallocatechin-3-Gallate Inhi-
bition of Myeloperoxidase and Its Counter-Regulation by Dietary Iron and Lipocalin 2 in Murine Model
of Gut Inflammation. The American journal of pathology. 2016; 186(4):912–26. doi: 10.1016/j.ajpath.
2015.12.004 PMID: 26968114.
5
2. Capeillere-Blandin C. Oxidation of guaiacol by myeloperoxidase: a two-electron-oxidized guaiacol tran-
sient species as a mediator of NADPH oxidation. The Biochemical journal. 1998; 336 (Pt 2):395–404.
PMID: 9820817; PubMed Central PMCID: PMCPMC1219884.
5
5
5
3. Schwyn B, Neilands JB. Universal chemical assay for the detection and determination of siderophores.
Analytical biochemistry. 1987; 160(1):47–56. PMID: 2952030.
4. Payne SM. Detection, isolation, and characterization of siderophores. Methods in enzymology. 1994;
235:329–44. PMID: 8057905.
5. Swamydas M, Lionakis MS. Isolation, purification and labeling of mouse bone marrow neutrophils for
functional studies and adoptive transfer experiments. J Vis Exp. 2013;(77: ):e50586. doi: 10.3791/
50586 PMID: 23892876; PubMed Central PMCID: PMCPMC3732092.
5
6. Choi HS, Kim JW, Cha YN, Kim C. A quantitative nitroblue tetrazolium assay for determining intracellu-
lar superoxide anion production in phagocytic cells. J Immunoassay Immunochem. 2006; 27(1):31–44.
doi: 10.1080/15321810500403722 PMID: 16450867.
57. Griswold DE, Martin LD, Badger AM, Breton J, Chabot-Fletcher M. Evaluation of the cutaneous anti-
inflammatory activity of azaspiranes. Inflamm Res. 1998; 47(2):56–61. PMID: 9535542.
58. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: esti-
mation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982; 78(3):206–9. PMID:
6276474.
59. Perron NR, Brumaghim JL. A review of the antioxidant mechanisms of polyphenol compounds related
to iron binding. Cell Biochem Biophys. 2009; 53(2):75–100. doi: 10.1007/s12013-009-9043-x PMID:
19184542.
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
20 / 21

Urolithin A Controls Neutrophilic Inflammation
6
6
0. Singh V, Yeoh BS, Xiao X, Kumar M, Bachman M, Borregaard N, et al. Interplay between enterobactin,
myeloperoxidase and lipocalin 2 regulates E. coli survival in the inflamed gut. Nature communications.
2015; 6:7113. doi: 10.1038/ncomms8113 PMID: 25964185.
1. Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, et al. Neutro-
phil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with patho-
physiology of inflammation, established markers, and disease activity. Journal of gastroenterology.
2012; 47(5):519–30. doi: 10.1007/s00535-011-0516-5 PMID: 22200942.
6
6
6
2. Feng BS, Chen X, Li P, Zheng PY, Chong J, Cho DB, et al. Expression of integrin alphavbeta6 in the
intestinal epithelial cells of patients with inflammatory bowel disease. N Am J Med Sci. 2009; 1(4):200–
4. doi: 10.4297/najms.2009.4200 PMID: 22666696; PubMed Central PMCID: PMCPMC3364666.
3. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease:
understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013; 6(4):295–308. doi: 10.1177/
1756283X13482996 PMID: 23814609; PubMed Central PMCID: PMCPMC3667473.
4. Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res
Pract. 2012; 2012:872716. doi: 10.1155/2012/872716 PMID: 23049548; PubMed Central PMCID:
PMCPMC3459241.
6
6
5. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nature reviews
Gastroenterology & hepatology. 2012; 9(2):88–96. doi: 10.1038/nrgastro.2011.244 PMID: 22183182.
6. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD, et al. Effects of
Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in
human subjects. The British journal of nutrition. 2010; 104(12):1831–8. doi: 10.1017/
S0007114510002874 PMID: 20815975.
6
6
7. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, et al. Regulation of abdominal adiposity
by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized con-
trolled trial. Eur J Clin Nutr. 2010; 64(6):636–43. doi: 10.1038/ejcn.2010.19 PMID: 20216555.
8. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of buty-
rate in intestinal and extraintestinal diseases. World journal of gastroenterology: WJG. 2011; 17
(
12):1519–28. doi: 10.3748/wjg.v17.i12.1519 PMID: 21472114; PubMed Central PMCID:
PMCPMC3070119.
6
9. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by
commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013; 504(7480):451–5.
doi: 10.1038/nature12726 PMID: 24226773; PubMed Central PMCID: PMC3869884.
7
0. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal
macrophage function via histone deacetylase inhibition. Proceedings of the National Academy of Sci-
ences of the United States of America. 2014; 111(6):2247–52. doi: 10.1073/pnas.1322269111 PMID:
24390544; PubMed Central PMCID: PMC3926023.
7
7
1. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free
radical biology & medicine. 2000; 28(12):1717–25. PMID: 10946213.
2. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate
immune response to bacterial infection by sequestrating iron. Nature. 2004; 432(7019):917–21. doi: 10.
1038/nature03104 PMID: 15531878.
73. Ishimoto H, Shibata M, Myojin Y, Ito H, Sugimoto Y, Tai A, et al. In vivo anti-inflammatory and antioxi-
dant properties of ellagitannin metabolite urolithin A. Bioorg Med Chem Lett. 2011; 21(19):5901–4. doi:
10.1016/j.bmcl.2011.07.086 PMID: 21843938.
PLOS ONE | DOI:10.1371/journal.pone.0156811 June 2, 2016
21 / 21